Answers are grounded in this paper and cite their sources.
Clinical trial shows minimal myopia rebound after treatment cessation in children, suggesting long-term efficacy of atropine.
The Childhood Atropine for Myopia Progression (CHAMP) study was registered in clinicaltrials.gov (NCT03350620, registration date November 17, 2017).
No takes yet. Share an insight, caveat, or question.
Zadnik et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: